Management
|
|
Anna Ljung, CEO , M.Sc. Econ.
Born 1980. Active in the company since 2006. Anna Ljung has more than 15 years of experience in the pharmaceutical industry, including as CFO of other biotech companies such as Athera Biotechnologies AB and Lipopetide AB and as independent technology licensing consultant. In addition to serving as CEO of Moberg Pharma, she also currently serves as Board member of Saniona AB and ADDvise Group AB and is Chairman of the Board of OncoZenge AB.
Shareholding:73 790 shares and 440 000 performance share units
|
 |
Anders Bröijersén, CMO, MD, PhD Born 1964. Active in the company since 2023. Anders Bröijersén is board certified in internal medicine and has a PhD from the department of Clinical Pharmacology at the Karolinska University Hospital. Anders has more than 15 years of experience from the pharmaceutical industry with leading positions within Medical Affairs, Clinical Development and Pharmacovigilance in companies such as Sobi, Boehringer-Ingelheim, MSD and InDex Pharmaceuticals. Shareholding: 84 shares and 0 performance share units |
 |
Annica Magnusson, Senior Director of Regulatory Affairs Born in 1963. Has worked for the company since 2013. Annica Magnusson is a pharmacist with more than 20 years of experience in international work within the pharmaceutical industry and Regulatory Affairs at AstraZeneca. Annica Mangusson has worked with the development and registration of pharmaceuticals, vaccines and medical devices in the EU, USA, Japan with several markets. Shareholding: 8 731 shares and 440 000 performance share units
|
 |
Mark Beveridge, Vice President Finance Born 1978. B. Com, GradDipCA. Active in the company since 2015. Mark Beveridge has more than 15 years of experience as an advisor in accounting, insurance and auditing, primarily from Crowe Horwath and Visma Services. Mark has also worked as an independent consultant within financial control, transaction consultancy and implementation of business systems. Shareholding: 155 373 shares and 440 000 performance share units |
 |
Jesper Lind, Head of Supply Born 1960. Has been active in the company since 2022. Jesper has a Master of Science in Chemical Engineering from Royal Institute of Technology Stockholm and Sydney University Australia. Jesper has 35 years of experience in Life Science of which 30 years is global experience from the pharmaceutical industry. Experience is mainly from Production, Supply, Supply Chain, Procurement, External sourcing, Newproduct introduction and Pharmaceutical development. Jesper has many years of global experience of crossfunctional Leadership at Leadership team level and has delivered extensive Change Management work based on Lean. Jesper has worked at Orexo, AstraZeneca, Astra and Pharmacia. Shareholding: 0 shares and 0 performance share units |
 |
Agneta Larhed, Vice President Pharmaceutical Innovation & Development Born 1964. Dr. Larhed has a broad experience of development, regulatory and quality within the pharmaceutical industry. She has held leading positions within the pharmaceutical industry and at regulatory authorities, including the Swedish MPA, Orexo and Q-Med. Dr Larhed is a pharmacist and obtained her PhD in Pharmaceutics from Uppsala university. Shareholding: 0 shares and 75 000 performance share units. |
Current shareholding is not automatically updated for the moment. Insiders no longer have obligation to report there shareholding. According to the regulatory requirements, the data shall be updated once a year.